ImmunityBio a annoncé lundi le lancement de ResQ215B, une étude clinique de phase 2 évaluant la thérapie cellulaire CD19 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results